<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920370</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1720-HV-101</org_study_id>
    <secondary_id>2018-004500-19</secondary_id>
    <nct_id>NCT04920370</nct_id>
  </id_info>
  <brief_title>Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability, pharmacokinetics,&#xD;
      pharmacodynamics, and immunogenicity of ALXN1720 administered subcutaneously (SC) or&#xD;
      intravenously (IV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized in a 3:1 ratio to receive the active treatment or placebo.&#xD;
&#xD;
      The study will be conducted in healthy adult participants, including participants of Japanese&#xD;
      descent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Of Treatment-emergent And Serious Adverse Events (TEAEs, SAEs)</measure>
    <time_frame>Up to 176 days following the first day of dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) Of ALXN1720 SC, ALXN1720 SC/rHuPH20, And ALXN1720 IV</measure>
    <time_frame>Up to 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Concentration-time Curve (AUC) Of ALXN1720 SC, ALXN1720 SC/rHuPH20, And ALXN1720 IV</measure>
    <time_frame>Up to 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Serum Concentrations Of Free Complement Component 5 (C5)</measure>
    <time_frame>Baseline, 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Serum Concentrations Of Total C5</measure>
    <time_frame>Baseline, 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Ex Vivo Chicken Red Blood Cell (cRBC) Hemolysis Activity</measure>
    <time_frame>Baseline, 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Antidrug Antibodies (ADAs) To ALXN1720</measure>
    <time_frame>Up to 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Bioavailability Of ALXN1720</measure>
    <time_frame>Up to 176 days following the first day of dosing</time_frame>
    <description>The absolute bioavailability for ALXN1720 SC will be defined by the ratio of the geometric means for AUC for ALXN1720 SC over ALXN1720 IV after a single dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of Incidence Of TEAEs And SAEs Between Healthy Non-Japanese Participants And Participants Of Japanese Descent</measure>
    <time_frame>Up to 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of Cmax Of ALXN1720 SC, ALXN1720 SC/rHuPH20, And ALXN1720 IV Between Healthy Non-Japanese Participants And Participants Of Japanese Descent</measure>
    <time_frame>Up to 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of AUC Of ALXN1720 SC, ALXN1720 SC/rHuPH20, And ALXN1720 IV Between Healthy Non-Japanese Participants And Participants Of Japanese Descent</measure>
    <time_frame>Up to 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of Change From Baseline In Serum Concentrations Of Free C5 Between Healthy Non-Japanese Participants And Participants Of Japanese Descent</measure>
    <time_frame>Baseline, 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of Change From Baseline In Serum Concentrations Of Total C5 Between Healthy Non-Japanese Participants And Participants Of Japanese Descent</measure>
    <time_frame>Baseline, 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of Change From Baseline In Serum Concentrations In Ex Vivo cRBC Hemolysis Activity Between Healthy Non-Japanese Participants And Participants Of Japanese Descent</measure>
    <time_frame>Baseline, 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison Of ADAs To ALXN1720 Between Healthy Non-Japanese Participants And Participants Of Japanese Descent</measure>
    <time_frame>Up to 176 days following the first day of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ALXN1720 Single Dose SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ALXN1720 SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALXN1720 Multiple Dose SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive multiple doses of ALXN1720 SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALXN1720 Single Dose SC + rHuPH20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ALXN1720 SC in combination with rHuPH20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALXN1720 Single Dose IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of ALXN1720 IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo SC or Placebo IV according to their assigned cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1720 SC</intervention_name>
    <description>ALXN1720 will be administered via SC route.</description>
    <arm_group_label>ALXN1720 Multiple Dose SC</arm_group_label>
    <arm_group_label>ALXN1720 Single Dose SC</arm_group_label>
    <arm_group_label>ALXN1720 Single Dose SC + rHuPH20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN1720 IV</intervention_name>
    <description>ALXN1720 will be administered via IV route.</description>
    <arm_group_label>ALXN1720 Single Dose IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuPH20</intervention_name>
    <description>rHuPH20 will be administered via SC route.</description>
    <arm_group_label>ALXN1720 Single Dose SC + rHuPH20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC</intervention_name>
    <description>Placebo will be administered via SC route.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo IV</intervention_name>
    <description>Placebo will be administered via IV route.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight within 50 to 90 kilograms (kg), inclusive, and body mass index within the&#xD;
             range of 18 to 29.9 kg/meter squared, inclusive.&#xD;
&#xD;
          -  Willing to follow protocol-specified contraception guidance while on treatment and for&#xD;
             6 months after the last dose of study treatment.&#xD;
&#xD;
          -  Vaccination with tetravalent meningococcal conjugate vaccine and serogroup B&#xD;
             meningococcal vaccine.&#xD;
&#xD;
          -  No clinically significant or relevant abnormalities as determined by medical history,&#xD;
             physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory&#xD;
             evaluation.&#xD;
&#xD;
          -  For the cohorts with Japanese participants, parents and grandparents must both be&#xD;
             Japanese, and participants must have resided for less than 5 years outside of Japan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or recurrent disease that could affect clinical assessments or clinical&#xD;
             laboratory evaluations.&#xD;
&#xD;
          -  History of complement deficiency or complement activity below the reference range.&#xD;
&#xD;
          -  Female participants who are breastfeeding.&#xD;
&#xD;
          -  Immunization with a live-attenuated vaccine 28 days prior to dosing on Day 1 or&#xD;
             planned vaccination during the course of the study. Immunization with inactivated or&#xD;
             recombinant influenza vaccine, or nucleoside-modified messenger ribonucleic acid or&#xD;
             recombinant COVID-19 vaccine is permitted.&#xD;
&#xD;
          -  Current tobacco smoking, history of illicit drug abuse, or history of significant&#xD;
             alcohol abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals Inc.</last_name>
    <phone>+1-855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Study Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALXN1720</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

